Cabozantinib Gets Breakthrough Tx Status for Differentiated Thyroid Cancer
The designation is supported by data from the randomized, double-blind, placebo-controlled phase 3 COSMIC-311 study.
Endocrine Cancer
Exposure to Light at Night May Increase Risk for Thyroid Cancer
Investigators tested the hypothesis that greater exposure to light at night (LAN) is associated with an increased risk for thyroid cancer by studying artificial outdoor LAN measured by satellite imagery in relation to thyroid cancer.
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
NCI-MATCH Trial Identifies Actionable Alterations in More Than One-Third of Patients With Cancer
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
Gavreto Gets Accelerated Approval for RET-Altered Thyroid Cancers
The approval was based on data from the phase 1/2 ARROW trial which evaluated the efficacy and safety of Gavreto in patients with RET-mutant MTC.
Reliability of Laboratory-Developed Tests Called Into Question
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
RET Inhibitor Demonstrates Efficacy in RET-Altered Thyroid Cancer
Treatment of RET-altered thyroid cancer with selpercatinib, a RET inhibitor, resulted in durable efficacy with a tolerable safety profile in a phase 1/2 trial.
The Twitter Effect on How Oncologists Conduct and Share Research
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
-
Loading...
-
Loading...
Next post in General Oncology
